Abstract |
This double-blind, placebo-controlled study investigated the efficacy and tolerability of adjunctive topiramate in 86 elderly Chinese patients with refractory partial epilepsy. Patients who had at least four seizures per 4 weeks during an 8-week baseline period, despite medication with up to three standard antiepileptic drugs (AEDs), were randomly assigned to receive topiramate (n = 46) or placebo (n = 40). Topiramate dosages were titrated (target dose 200 mg/day orally) for 8 weeks and maintained at stable levels for another 12 weeks; concomitant AEDs continued at original dosages. All patients completed the study: 47.8% in the topiramate group and 7.5% on placebo reached ≥ 50% reduction in complex partial seizures. In the topiramate group, the most common adverse events were dizziness, somnolence, fatigue, headache and difficulty with memory; most events were transient and mild or moderate in severity. It was concluded that 200 mg/day topiramate was effective and well-tolerated in elderly patients with refractory partial epilepsy.
|
Authors | L Zhang, J Huang, J-H Zhuang, L-Q Huang, Z-X Zhao |
Journal | The Journal of international medical research
(J Int Med Res)
Vol. 39
Issue 2
Pg. 408-15
( 2011)
ISSN: 1473-2300 [Electronic] England |
PMID | 21672344
(Publication Type: Journal Article, Randomized Controlled Trial)
|
Chemical References |
- Anticonvulsants
- Topiramate
- Fructose
|
Topics |
- Administration, Oral
- Aged
- Anticonvulsants
(administration & dosage, therapeutic use)
- Asian People
- China
- Epilepsies, Partial
(drug therapy)
- Female
- Fructose
(administration & dosage, adverse effects, analogs & derivatives, therapeutic use)
- Humans
- Male
- Seizures
(drug therapy)
- Topiramate
|